CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:COVID-19 in patients with cancer: Risks and precautions.
COVID-19 in patients with cancer: Risks and precautions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)属于冠状病毒科,可引起 2019 冠状病毒病(COVID-19)。COVID-19 表型从无症状、轻症到严重急性呼吸窘迫综合征(ARDS)不等;后者常导致死亡,尤其见于有基础疾病者。据报道,癌症患者(尤其是肺癌和血液系统恶性肿瘤患者)发生 COVID-19 严重并发症和死亡的风险较高。CAR-T 细胞治疗等某些癌症治疗可引发细胞因子风暴,而这也是重症 COVID-19 的标志。因此,接受 CAR-T 细胞治疗的患者若感染 COVID-19,风险可能更高,可考虑采用抗细胞因子治疗。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases.
It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19.
Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。